Ristić Dragana, Vukosavljević Miroslav, Draganić Biljana, Cerović Vesna, Petrović Nenad, Janićijević-Petrović Mirjana
Ophthalmology Clinic, Military Medical Academy, Belgrade, Serbia.
Vojnosanit Pregl. 2013 Jul;70(7):660-3. doi: 10.2298/vsp110311047r.
BACKGROUND/AIM: Age-related macular degeneration (AMD) is a leading cause of the loss of central visual acuity in population older than 70 years. We can distinguish wet and dry form of AMD. The aim of the study was to present our early results in treatment of the wet (neovascular) form of AMD with intravitreal administration of bevacizumab.
The study included 39 patients. Each patient underwent a complete ophthalmological examination, fluorescein angiography (FA) and optical coherence tomography (OCT). All the patients received 1.25 mg of intravitreal bevacizumab (0.05 mL of commercial phial of Avastin). The total of three doses was given with a one-month interval between doses.
Among 39 patients, 24 were women and 15 men. The average best corrected visual acuity (BCVA) was improved from 0.09 before the therapy to 0.24 after the administration of all the three doses of bevacizumab (p < 0.001). The average central macular thickness (CMT) measured by OCT was improved from 474 microm in the beginning to 341 microm after the administration of all the three doses of the drug (p < 0.001). There were no side effects.
Our short-term experience indicates that intravitreal administration of three doses of bevacizumab in one-month intervals between the doses leads to a significant reduction of macular edema and improvement of BCVA in patients with neovascular AMD.
背景/目的：年龄相关性黄斑变性（AMD）是70岁以上人群中心视力丧失的主要原因。AMD可分为湿性和干性两种类型。本研究的目的是展示玻璃体内注射贝伐单抗治疗湿性（新生血管性）AMD的早期结果。
该研究纳入了39例患者。每位患者均接受了全面的眼科检查、荧光素血管造影（FA）和光学相干断层扫描（OCT）。所有患者均接受了1.25mg玻璃体内贝伐单抗（0.05mL商业瓶装阿瓦斯汀）。共给予三剂，剂量间隔为1个月。
39例患者中，女性24例，男性15例。平均最佳矫正视力（BCVA）从治疗前的0.09提高到三剂贝伐单抗注射后的0.24（p<0.001）。通过OCT测量的平均中心黄斑厚度（CMT）从开始时的474微米改善到三剂药物注射后的341微米（p<0.001）。未出现副作用。
我们的短期经验表明，每隔1个月玻璃体内注射三剂贝伐单抗可显著减轻新生血管性AMD患者的黄斑水肿并改善BCVA。
